Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis.

Rokavec M, Bouznad N, Hermeking H.

Cell Mol Gastroenterol Hepatol. 2019;7(4):783-802. doi: 10.1016/j.jcmgh.2019.02.003. Epub 2019 Mar 1.

2.

Ap4 is rate limiting for intestinal tumor formation by controlling the homeostasis of intestinal stem cells.

Jaeckel S, Kaller M, Jackstadt R, Götz U, Müller S, Boos S, Horst D, Jung P, Hermeking H.

Nat Commun. 2018 Sep 3;9(1):3573. doi: 10.1038/s41467-018-06001-x.

3.

Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1.

Öner MG, Rokavec M, Kaller M, Bouznad N, Horst D, Kirchner T, Hermeking H.

Gastroenterology. 2018 Dec;155(6):1868-1882. doi: 10.1053/j.gastro.2018.08.011. Epub 2018 Aug 10.

PMID:
30099074
4.

Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer.

Schmidt EM, Lamprecht S, Blaj C, Schaaf C, Krebs S, Blum H, Hermeking H, Jung A, Kirchner T, Horst D.

J Exp Med. 2018 Jun 4;215(6):1693-1708. doi: 10.1084/jem.20171455. Epub 2018 May 16.

5.

PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer.

Lamprecht S, Kaller M, Schmidt EM, Blaj C, Schiergens TS, Engel J, Jung A, Hermeking H, Grünewald TGP, Kirchner T, Horst D.

Clin Cancer Res. 2018 Apr 15;24(8):1974-1986. doi: 10.1158/1078-0432.CCR-17-2572. Epub 2018 Feb 1.

6.

Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity.

Kaller M, Götz U, Hermeking H.

Oncotarget. 2017 Nov 1;8(61):102783-102800. doi: 10.18632/oncotarget.22245. eCollection 2017 Nov 28.

7.

Multicolor lineage tracing reveals clonal architecture and dynamics in colon cancer.

Lamprecht S, Schmidt EM, Blaj C, Hermeking H, Jung A, Kirchner T, Horst D.

Nat Commun. 2017 Nov 10;8(1):1406. doi: 10.1038/s41467-017-00976-9.

8.

Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression.

Rokavec M, Kaller M, Horst D, Hermeking H.

Sci Rep. 2017 Jul 5;7(1):4687. doi: 10.1038/s41598-017-04234-2.

9.

Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells.

Li H, Rokavec M, Jiang L, Horst D, Hermeking H.

Gastroenterology. 2017 Aug;153(2):505-520. doi: 10.1053/j.gastro.2017.04.017. Epub 2017 Apr 20.

PMID:
28435028
10.

miR-34a and miR-34b/c Suppress Intestinal Tumorigenesis.

Jiang L, Hermeking H.

Cancer Res. 2017 May 15;77(10):2746-2758. doi: 10.1158/0008-5472.CAN-16-2183. Epub 2017 Mar 31.

11.

Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations.

Blaj C, Schmidt EM, Lamprecht S, Hermeking H, Jung A, Kirchner T, Horst D.

Cancer Res. 2017 Apr 1;77(7):1763-1774. doi: 10.1158/0008-5472.CAN-16-2821. Epub 2017 Feb 15.

12.

Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis.

Rokavec M, Horst D, Hermeking H.

Cancer Res. 2017 Apr 15;77(8):1854-1867. doi: 10.1158/0008-5472.CAN-16-3236. Epub 2017 Jan 27.

13.

ADNP Is a Therapeutically Inducible Repressor of WNT Signaling in Colorectal Cancer.

Blaj C, Bringmann A, Schmidt EM, Urbischek M, Lamprecht S, Fröhlich T, Arnold GJ, Krebs S, Blum H, Hermeking H, Jung A, Kirchner T, Horst D.

Clin Cancer Res. 2017 Jun 1;23(11):2769-2780. doi: 10.1158/1078-0432.CCR-16-1604. Epub 2016 Nov 30.

14.

Interplay Between Transcription Factors and MicroRNAs Regulating Epithelial-Mesenchymal Transitions in Colorectal Cancer.

Kaller M, Hermeking H.

Adv Exp Med Biol. 2016;937:71-92. doi: 10.1007/978-3-319-42059-2_4. Review.

PMID:
27573895
15.

p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1.

Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, Meyer B, Kusov Y, von Brunn B, Bairad DR, Hünten S, Drosten C, Hermeking H, Leonhardt H, Mann M, Hilgenfeld R, von Brunn A.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5192-201. doi: 10.1073/pnas.1603435113. Epub 2016 Aug 12.

16.

Deletion of 14-3-3σ sensitizes mice to DMBA/TPA-induced papillomatosis.

Winter M, Lodygin D, Verdoodt B, Hermeking H.

Oncotarget. 2016 Jul 26;7(30):46862-46870. doi: 10.18632/oncotarget.10478.

17.

CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.

Woischke C, Blaj C, Schmidt EM, Lamprecht S, Engel J, Hermeking H, Kirchner T, Horst D.

Oncotarget. 2016 May 24;7(21):31350-60. doi: 10.18632/oncotarget.8912.

18.

lnflammation-induced epigenetic switches in cancer.

Rokavec M, Öner MG, Hermeking H.

Cell Mol Life Sci. 2016 Jan;73(1):23-39. doi: 10.1007/s00018-015-2045-5. Epub 2015 Sep 22. Review.

PMID:
26394635
19.

p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses.

Hünten S, Kaller M, Drepper F, Oeljeklaus S, Bonfert T, Erhard F, Dueck A, Eichner N, Friedel CC, Meister G, Zimmer R, Warscheid B, Hermeking H.

Mol Cell Proteomics. 2015 Oct;14(10):2609-29. doi: 10.1074/mcp.M115.050237. Epub 2015 Jul 16.

21.
22.

Corrigendum. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.

Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, Slotta-Huspenina J, Bader FG, Greten FR, Hermeking H.

J Clin Invest. 2015 Mar 2;125(3):1362. doi: 10.1172/JCI81340. Epub 2015 Mar 2. No abstract available.

23.

The p53/microRNA connection in gastrointestinal cancer.

Rokavec M, Li H, Jiang L, Hermeking H.

Clin Exp Gastroenterol. 2014 Sep 30;7:395-413. doi: 10.2147/CEG.S43738. eCollection 2014. Review.

24.

AP4 is required for mitogen- and c-MYC-induced cell cycle progression.

Jackstadt R, Hermeking H.

Oncotarget. 2014 Sep 15;5(17):7316-27.

25.

Colorectal cancers mimic structural organization of normal colonic crypts.

Cernat L, Blaj C, Jackstadt R, Brandl L, Engel J, Hermeking H, Jung A, Kirchner T, Horst D.

PLoS One. 2014 Aug 11;9(8):e104284. doi: 10.1371/journal.pone.0104284. eCollection 2014.

26.

Identification of microRNA targets by pulsed SILAC.

Kaller M, Oeljeklaus S, Warscheid B, Hermeking H.

Methods Mol Biol. 2014;1188:327-49. doi: 10.1007/978-1-4939-1142-4_23.

PMID:
25059622
27.

ZNF281/ZBP-99: a new player in epithelial-mesenchymal transition, stemness, and cancer.

Hahn S, Hermeking H.

J Mol Med (Berl). 2014 Jun;92(6):571-81. doi: 10.1007/s00109-014-1160-3. Epub 2014 May 18. Review.

PMID:
24838609
28.

The p53/miR-34 axis in development and disease.

Rokavec M, Li H, Jiang L, Hermeking H.

J Mol Cell Biol. 2014 Jun;6(3):214-30. doi: 10.1093/jmcb/mju003. Epub 2014 May 9. Review.

PMID:
24815299
29.

Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.

Knösel T, Altendorf-Hofmann A, Lindner L, Issels R, Hermeking H, Schuebbe G, Gibis S, Siemens H, Kampmann E, Kirchner T.

J Clin Pathol. 2014 Jul;67(7):592-8. doi: 10.1136/jclinpath-2013-202106. Epub 2014 Apr 19.

PMID:
24747207
30.

MicroRNAs as regulators and mediators of c-MYC function.

Jackstadt R, Hermeking H.

Biochim Biophys Acta. 2015 May;1849(5):544-53. doi: 10.1016/j.bbagrm.2014.04.003. Epub 2014 Apr 13. Review.

PMID:
24727092
31.

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.

Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, Slotta-Huspenina J, Bader FG, Greten FR, Hermeking H.

J Clin Invest. 2014 Apr;124(4):1853-67. doi: 10.1172/JCI73531. Epub 2014 Mar 18. Erratum in: J Clin Invest. 2015 Mar 2;125(3):1362.

32.

miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment.

Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, Jiang L, Öner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY.

Cell Rep. 2014 Mar 27;6(6):1000-1007. doi: 10.1016/j.celrep.2014.02.023. Epub 2014 Mar 13. Erratum in: Cell Rep. 2015 Sep 29;12(12):2181.

33.

p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer.

Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H.

Cancer Res. 2014 Jan 15;74(2):532-42. doi: 10.1158/0008-5472.CAN-13-2203. Epub 2013 Nov 27.

34.

SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition.

Hahn S, Jackstadt R, Siemens H, Hünten S, Hermeking H.

EMBO J. 2013 Nov 27;32(23):3079-95. doi: 10.1038/emboj.2013.236. Epub 2013 Nov 1.

35.
36.

Genome-wide analysis of c-MYC-regulated mRNAs and miRNAs, and c-MYC DNA binding by next-generation sequencing.

Jackstadt R, Menssen A, Hermeking H.

Methods Mol Biol. 2013;1012:145-85. doi: 10.1007/978-1-62703-429-6_11.

PMID:
24006064
37.

AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation.

Jackstadt R, Jung P, Hermeking H.

Cell Death Dis. 2013 Aug 15;4:e775. doi: 10.1038/cddis.2013.282.

38.

AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer.

Jackstadt R, Röh S, Neumann J, Jung P, Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A, Hermeking H.

J Exp Med. 2013 Jul 1;210(7):1331-50. doi: 10.1084/jem.20120812. Epub 2013 Jun 10.

39.

The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival.

Hohenauer T, Berking C, Schmidt A, Haferkamp S, Senft D, Kammerbauer C, Fraschka S, Graf SA, Irmler M, Beckers J, Flaig M, Aigner A, Höbel S, Hoffmann F, Hermeking H, Rothenfusser S, Endres S, Ruzicka T, Besch R.

EMBO Mol Med. 2013 Jun;5(6):919-34. doi: 10.1002/emmm.201201862. Epub 2013 May 13.

40.

MicroRNA-34a regulates cardiac ageing and function.

Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, Tréguer K, Carmona G, Bonauer A, Horrevoets AJ, Didier N, Girmatsion Z, Biliczki P, Ehrlich JR, Katus HA, Müller OJ, Potente M, Zeiher AM, Hermeking H, Dimmeler S.

Nature. 2013 Mar 7;495(7439):107-10. doi: 10.1038/nature11919. Epub 2013 Feb 20.

PMID:
23426265
41.

The p53/microRNA network in cancer: experimental and bioinformatics approaches.

Hünten S, Siemens H, Kaller M, Hermeking H.

Adv Exp Med Biol. 2013;774:77-101. doi: 10.1007/978-94-007-5590-1_5. Review.

PMID:
23377969
42.

Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.

Kriegl L, Jung A, Horst D, Rizzani A, Jackstadt R, Hermeking H, Gallmeier E, Gerbes AL, Kirchner T, Göke B, De Toni EN.

PLoS One. 2012;7(12):e51654. doi: 10.1371/journal.pone.0051654. Epub 2012 Dec 20.

43.

Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer.

Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, Hermeking H.

Clin Cancer Res. 2013 Feb 1;19(3):710-20. doi: 10.1158/1078-0432.CCR-12-1703. Epub 2012 Dec 14.

44.

Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis.

Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18384-9. doi: 10.1073/pnas.1209171109. Epub 2012 Oct 22.

45.

MicroRNAs in the p53 network: micromanagement of tumour suppression.

Hermeking H.

Nat Rev Cancer. 2012 Sep;12(9):613-26. doi: 10.1038/nrc3318. Epub 2012 Aug 17. Review.

PMID:
22898542
46.

c-MYC and SIRT1 locked in a vicious cycle.

Menssen A, Hermeking H.

Oncotarget. 2012 Feb;3(2):112-3. No abstract available.

47.

The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.

Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, Larsson LG, Hermeking H.

Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):E187-96. doi: 10.1073/pnas.1105304109. Epub 2011 Dec 21.

48.

miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions.

Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H.

Cell Cycle. 2011 Dec 15;10(24):4256-71. doi: 10.4161/cc.10.24.18552. Epub 2011 Dec 15.

PMID:
22134354
49.

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Körner S, Wang W, Boccaccio C, Thorgeirsson SS, Comoglio PM, Hermeking H, Nikitin AY.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14240-5. doi: 10.1073/pnas.1017536108. Epub 2011 Aug 9.

50.

Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis.

Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Röh S, Hoffmann R, Warscheid B, Hermeking H.

Mol Cell Proteomics. 2011 Aug;10(8):M111.010462. doi: 10.1074/mcp.M111.010462. Epub 2011 May 12.

Supplemental Content

Loading ...
Support Center